NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, platform, NextCure studies various immune cells to discover and understand targets and structural components of immune cells and their impact on immune function in order to develop immunomedicines. NextCure is focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. Source
No articles found.
Founded in 2006 and headquartered in San Diego, Adamis (ADMP) is a specialty bioph...
Founded in 2006 and headquartered in San Diego,...
Urovant Sciences is a clinical-stage biopharmaceutical company focused on developi...
Urovant Sciences is a clinical-stage biopharmac...
SINTX Technologies is a commercial biomaterial company focused on using its silico...
SINTX Technologies is a commercial biomaterial ...
Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...
Adaptimmune is a leader in TCR T-cell therapy, ...
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigene...
Epizyme, Inc. is a clinical stage biopharmaceut...
Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused ...
Sarepta Therapeutics is a U.S. commercial-stage...
Midatech is an international specialty pharmaceutical company focused on the devel...
Midatech is an international specialty pharmace...
Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceut...
Hutchison China MediTech Limited, known as Chi-...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...
Merck KGaA, Darmstadt, Germany, a leading scien...
Our strategy is to be known as âthe prostate cancer companyâ. We aspire to be ...
Our strategy is to be known as âthe prostate ...
Join the National Investor Network and get the latest information with your interests in mind.